Full Press Release Details
Media Advisory - Oncolytics Biotech Inc. Announces Participation
in the 4th Annual Immuno-Oncology Summit
CALGARY, Aug. 30, 2016 /CNW/ - Dr. Brad Thompson, President
and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY), will present at the 4th Annual Immuno-Oncology
Summit in a session today, Tuesday, August 30th. The summit takes place from August 29th to September
A copy of the presentation will be made available on the company's
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused
on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety
of later-stage, randomized human trials in various indications using REOLYSIN , its proprietary formulation of the
human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
SOURCE Oncolytics Biotech Inc.
For further information: NATIONAL Equicom, Nick Hurst, 320
Front Street W, Suite 1600, Toronto, Ontario, M5V 3B6, Tel: 416.586.1942, nhurst@national.ca; NATIONAL Equicom, Michael Moore,
San Diego, CA, Tel: 858.886.7813, mmoore@national.ca; Dian Griesel, Inc., Susan Forman, 335 West 38th Street, 3rd Floor, New York,
NY 10018, Tel: 212.825.3210, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 06:30e 30-AUG-16